Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

TAVR has long been an effective strategy to treat aortic stenosis. However, ventricular damage starts further before symptom onset, also affecting the left ventricle, pulmonary vessels, the right ventricle, the tricuspid valve, and the right atrium. 

La enfermedad vascular periférica se asocia a más eventos en el TAVI

It increases arterial afterload and uncouples the right ventricle and the pulmonary artery, defined by transthoracic echocardiogram as the relationship between the tricuspid annular plane systolic excursion (TAPSE) and  pulmonary artery systolic pressure (PASP), TAPSE/PSAP.

 A reduction in this relationship (≤0.55 mmHg) is associated with unfavorable evolution.

The study looked at PARTNER 3 patients. 222 of these patients (38.9%) presented RV-PA uncoupling TAPSE/PSAP ≤0.55 mmHg; and 348, RV-PA coupling TAPSE/PSAP >0.55 mmHg.

Primary end point was a composite of all cause death, stroke and rehospitalization at 2 years. 

Lea tambien: Should We Start Using Ultra-Thin Struts?

The populations were similar, mean age was 74, 66% were men, 30% were diabetic. Those presenting uncoupling had more arrythmia and higher BMP. 

After two years, primary end point was higher among those presenting uncoupling (19.1% vs 9.9%; HR: 2.03; 95% CI: 1.29-3.19; P=0.002), as was all cause (5.9% vs 0.6%; P < 0.001), and cardiovascular mortality (4.1% vs 0.6%; P=0.003) and rehospitalization (13.5% vs 7.3% P=0.02). Stroke rate (24.2% vs 14.2%; HR: 1.83; 95% CI: 0.98-3.41; P ¼ 0.053ke) was fairly low, with no difference.

Uncoupled patients undergoing transcatheter aortic valve replacement had a higher incidence of primary end point (24.2% vs 14.2% P=0.05).

Read also: Devices to Prepare Severely Calcified Lesions: Is There a Difference When Assessed by Intravascular Imaging?

At multivariable analysis, uncoupling resulted an independent predictor of primary end point at 2 years. 

Conclusion

In low risk symptomatic aortic stenosis patients undergoing TAVR or SAVR, baseline right ventricle and pulmonary artery uncoupling, defined as TAPSE/PSAP ≤0.55 mmHg, was associated to clinical adverse events at 2 years, including all cause and cardiovascular mortality, and rehospitalization. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Right Ventricle-Pulmonary Artery Coupling on Clinical Outcomes in the PARTNER 3 Trial.

Reference: Thomas J. Cahill, et al. J Am Coll Cardiol Intv 2022;15:1823–1833.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...